Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: Preliminary results

被引:10
作者
Hussain, A
Dawson, N
Amin, P
Naslund, M
Engstrom, C
Chen, T
机构
[1] Univ Maryland, Greenebaum Canc Ctr, Sch Med, Baltimore, MD 21201 USA
[2] Baltimore Vet Affairs Med Ctr, Dept Vet Affairs, Baltimore, MD USA
关键词
D O I
10.1053/sonc.2001.26895
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An increasingly important issue in the management of prostate cancer is the occurrence of biochemical failure (ie, increasing serum prostate-specific antigen [PSA] levels) in patients with clinically localized prostate cancer who initially underwent definitive treatments with curative intent (prostatectomy and/or radiation therapy). This pilot trial evaluated chemotherapy followed by hormone therapy for a defined period in patients with biochemical (and possibly clinical) recurrence after initial local therapies for localized/locally advanced prostate cancer. Patients who developed increasing PSA > 4 ng/mL after initial prostatectomy and/or radiation therapy received docetaxel, 70 mg/m2 every 3 weeks for up to 6 courses, followed by 4 months of total androgen suppression (using a luteinizing hormone-releasing hormone agonist plus bicalutamide, 50 mg/d) and 8 months of peripheral androgen blockade (using finasteride, 5 mg/d, plus bicalutamide, 50 mg/d). Twenty-seven patients have enrolled to date, 23 of whom received four or six cycles of docetaxel before hormonal therapies. Seventeen (74%) of 23 patients who completed four to six cycles of chemotherapy had a ≥40% decrease in PSA, and 16 (89%) of 18 patients who completed 4 months of total androgen suppression achieved PSA values of ≤0.1. The most common hematologic toxicity was grade 3/4 neutropenia; grade 3 nonhematologic toxicities were rare, and no grade 4 nonhematologic toxicities were reported. Thus, the preliminary results suggest that docetaxel before hormonal therapy includes a PSA response in many prostate cancer patients with biochemical failure after definitive local therapies. Copyright © 2001 by W.B. Saunders Company.
引用
收藏
页码:22 / 31
页数:10
相关论文
共 19 条
[1]  
Do T, 1998, CANCER J SCI AM, V4, P324
[2]  
Forman JD, 1998, ONCOLOGY-NY, V12, P33
[3]   IS PROSTATE SPECIFIC ANTIGEN OF CLINICAL IMPORTANCE IN EVALUATING OUTCOME AFTER RADICAL PROSTATECTOMY [J].
FRAZIER, HA ;
ROBERTSON, JE ;
HUMPHREY, PA ;
PAULSON, DF .
JOURNAL OF UROLOGY, 1993, 149 (03) :516-518
[4]  
Friedland D, 1999, SEMIN ONCOL, V26, P19
[5]  
Gingrich JR, 1996, CANCER RES, V56, P4096
[6]   RADIOIMMUNOSCINTIGRAPHY WITH (111)INDIUM LABELED CYT-356 FOR THE DETECTION OF OCCULT PROSTATE-CANCER RECURRENCE [J].
KAHN, D ;
WILLIAMS, RD ;
SELDIN, DW ;
LIBERTINO, JA ;
HIRSCHHORN, M ;
DREICER, R ;
WEINER, GJ ;
BUSHNELL, D ;
GULFO, J .
JOURNAL OF UROLOGY, 1994, 152 (05) :1490-1495
[7]   ROLE OF CALCIUM IN THE PROGRAMMED DEATH OF RAT PROSTATIC GLANDULAR CELLS [J].
MARTIKAINEN, P ;
ISAACS, J .
PROSTATE, 1990, 17 (03) :175-187
[8]   Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer [J].
McDonnell, TJ ;
Navone, NM ;
Troncoso, P ;
Pisters, LL ;
Conti, C ;
vonEschenbach, AC ;
Brisbay, S ;
Logothetis, CJ .
JOURNAL OF UROLOGY, 1997, 157 (02) :569-574
[9]  
MEDINA P, 1999, P AN M AM SOC CLIN, V18, P347
[10]  
MOUL JW, 1998, CLIN ONCOL UPDATES, V1, P1